State Street SPDR S&P Biotech ETF
741 hedge funds and large institutions have $8.01B invested in State Street SPDR S&P Biotech ETF in 2023 Q4 according to their latest regulatory filings, with 143 funds opening new positions, 171 increasing their positions, 269 reducing their positions, and 67 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding in top 10
Funds holding in top 10: →
more capital invested
Capital invested by funds: $ → $
more funds holding
Funds holding: →
7.03% less ownership
Funds ownership: 117.48% → 110.45% (-7%)
36% less repeat investments, than reductions
Existing positions increased: 171 | Existing positions reduced: 269
38% less call options, than puts
Call options by funds: $2.01B | Put options by funds: $3.26B
Holders
741
Holding in Top 10
23
Calls
$2.01B
Puts
$3.26B
Top Buyers
| 1 | +$330M | |
| 2 | +$251M | |
| 3 | +$134M | |
| 4 |
MCM
Moore Capital Management
New York
|
+$129M |
| 5 |
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
|
+$101M |
Top Sellers
| 1 | -$344M | |
| 2 | -$198M | |
| 3 | -$164M | |
| 4 |
Citigroup
New York
|
-$112M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$63.9M |